Boston-based biotech startup GentiBio this week announced a $20 million funding round and licensing deals with two Seattle research institutions.
The company aims to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases by developing engineered regulatory T cells, or Tregs. It is licensing technology from Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRI), and Israel-based MIGAL Galilee Research Institute (MIGAL).
Researchers from both Seattle Children’s and BRI helped launch GentiBio. The company is led by longtime biotech and life sciences industry exec Adel Nada.
“The technologies licensed from these premier research institutions are mature and well-differentiated, and will be further optimized in sponsored research collaborations with the scientific teams that discovered them to advance novel and potent therapeutics with the potential to treat and cure serious autoimmune and inflammatory diseases,” Nada said in a statement.
Investors in the seed round include OrbiMed, Novartis Venture Fund, and RA Capital Management.
GeekWire’s coverage this week is underwritten by BCRA
As you plan for the future, consider what spaces will cultivate employee engagement, reflect your brand, and advance your goals. Digital work will continue, but it can’t recreate the energy that physical proximity offers. Think of it this way, you can listen to an album or go to a concert. You’re hearing the same music, but each experience is unique. The same is true for a workplace, and we can help you reimagine your office to maximize your investment.
Hear more about how to rethink your future workspace here
View the original article here
from WordPress https://cybersonday689753477.wordpress.com/2020/08/21/new-biotech-startup-gentibio-lands-20m-inks-licensing-deals-with-seattle-childrens-and-bri/
No hay comentarios.:
Publicar un comentario